Clovis Oncology (NASDAQ:CLVS) announces
that Rubraca (rucaparib), an oral, small molecule inhibitor of PARP1,
PARP2 and PARP3 is now available and reimbursed in France.
Rubraca is an option for monotherapy maintenance
treatment for adults with relapsed, platinum-sensitive high-grade
epithelial ovarian, fallopian tube or primary peritoneal cancer that has
responded to platinum-based chemotherapy.
With Rubraca now available in France, it is now a treatment option for eligible patients in Germany, England and Italy.
Shares are up 4% premarket.
https://seekingalpha.com/news/3537241-clovis-oncologys-rubraca-now-available-in-france-shares-up-4-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.